RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
Aptar Pharma, leader in respiratory drug delivery solutions, and RDD Online® are pleased to announce their co-organization of RDD® Europe 2025, which will be held in-person from Tuesday, May 6 to Friday, May 9, 2025 at the Estoril Congress Center in Estoril, Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227163353/en/
RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online (Graphic: Business Wire)
Celebrating 20 years of RDD Europe and one of the largest and highly regarded international respiratory health conferences, RDD Europe 2025 will host over 500 scientists, engineers, clinicians and business professionals engaged in all aspects of nasal and pulmonary drug delivery.
With curated and peer reviewed content organized in six Knowledge Spaces, speakers, workshops, poster presenters and exhibitors will share timely, actionable insights under the following themes:
- Bench to Bedside: Emerging Therapies and Clinical Advances
- Inspiring Dry Powder Inhalation: Formulation Science and Device Design
- MDIs in Transition: Evolving Science and Regulations
- Advanced Inhalation: AI and Data Driven Design
- Aqueous Agenda: Soft Mist Inhalers and Nebulizer Advances
- Nasal Spotlight: Advances in Systemic and Nose-to-Brain Delivery.
Twelve delegate-selectable industry Workshops will take place on Wednesday, May 7, providing practical and interactive demonstrations of innovative technologies, products and capabilities in a small group setting.
An integrated Poster & Exhibition session will run throughout the 3-day conference, ensuring ample opportunity for networking, with 70 exhibit tables and 72 posters showcasing academic and industry research, and development breakthroughs across established and emerging nasal and pulmonary drug delivery platforms.
To complement in-person activities, RDD Europe 2025 will also include extended online access from April 29 to June 30, 2025 to on-demand presentations and company profiles. In addition, almost 3,000 peer-reviewed speaker and poster papers will be available to delegates for 12 months after the conference.
The conference will open with a Welcome Cocktail Reception on the evening of Tuesday, May 6, and Aptar Pharma will sponsor a Gala Dinner at a scenic location in Estoril on Thursday, May 8.
As a global leader in OINDP device design and technology, Aptar Pharma is proud to be a Co-Organizer of RDD Europe 2025 and will host a workshop on May 7. Entitled “Ready for Clinical Trials in 1 Hour: A Roadmap to Success,” this workshop will be co-presented by Jonathan Mulpas, Director Business Development Pulmonary Category, Aptar Pharma, Will Ganley, Manager, Computational Pharmaceutics, Nanopharm, an Aptar Pharma company, and Carolina Dantas, Head of Medical & Scientific Affairs, Pulmotree.
“Estoril is a great location to celebrate 20 years of RDD Europe conferences. I can’t wait to catch up with friends and organizations who have returned year after year since RDD Europe 2005 was first held in Paris,” commented Richard Dalby, one of the conference organizers. “So much has changed since then, and the innovation I’ve witnessed seems poised to have direct benefits on patient health, healthcare provider choice and environmental sustainability.”
Added Carolyn Penot, Director of Operational Marketing at Aptar Pharma, “RDD Europe 2025 is a must-attend event, and this year’s Knowledge Spaces will represent the latest thinking in nasal and pulmonary drug delivery. We look forward to celebrating 20 years of RDD Europe with our conference participants.”
To register as a delegate or learn more about sponsorship opportunities, visit the RDD Europe 2025 website.
About RDD Online
RDD Online manages the organization of Respiratory Drug Delivery conferences in the U.S., and partners with Aptar Pharma to run RDDevents in Europe and Asia. These international conferences, focused on technologies and solutions to improve patient health, routinely attract over 500 delegates from 25 countries representing academia, industry and regulatory agencies. RDD Online also supplies realistic mouth throat models, Nephele mixing inlets and dose collection tubes. We offer scientific and technical publications, web-based training, and a company directory of organizations active in pulmonary and nasal drug delivery. For more information, please visit www.rddonline.com.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has approximately 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227163353/en/
Contacts
Media Contact
RDD Online, LLC
Richard Dalby
+1 (804) 239 1978
rdalby@rx.umaryland.edu
Media Contact
Aptar Pharma
Ciara Jackson
+49 1511 951 6502
ciara.jackson@aptar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 22:48:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 18:46:00 EEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 18:44:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 18:00:00 EEST | Press release
LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances automated testing workflows by enabling the generation of new test cases using real execution data. Developers can leverage
The Six Winning Projects of the 12 th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open27.5.2025 17:58:00 EEST | Press release
Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/ The Award Ceremony of the 12th edition of the IBSA Foundation Fellowship The € 32,000 fellowships were awarded to research projects in five scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/orthopaedics/rheumatology and healthy aging/regenerative medicine. In particular, this latter category has attracted growing interes
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom